Literature DB >> 16935538

The endocrine system in treated patients with classical galactosemia.

M Estela Rubio-Gozalbo1, Bianca Panis, Luc J I Zimmermann, Leo J Spaapen, P P C A Menheere.   

Abstract

Endocrine abnormalities in classical galactosemia, female hypergonadotropic hypogonadism and low thyroxin in neonates, have been reported. Galactosemia is a secondary glycosylation disorder and hypoglycosylation of glycoproteins has a role in this dysfunction. Hypoglycosylation, improves but does not completely disappear with dietary treatment. Our aim was to evaluate the endocrine system in treated patients (n = 37, 25 females, 12 males, age 5-19 years). Endocrine determinations were compared to age and gender matched reference ranges. Sample t-test (to test differences with reference population) and linear regression analysis between hGH (growth hormone), IGF-1 (insulin-like growth factor), IGFBP-3 (insulin growth factor binding protein), FSH (follicle stimulating hormone), LH (luteinizing hormone) and GALT activity, and soy intake, was carried out. Mean IGF-1 Z-score was -0.98 +/- 0.84 (range -2.59 to 1.21) (P < 0.001) in females and 0.03 +/- 0.55 (range -1.0 to 0.89) (P = 0.84) in males. Mean IGFBP-3 Z-score was -0.98 +/- 1.3 (range -3.0 to 2.0) (P < 0.001) in females and 0.26 +/- 0.93 (range -0.94 to 2.0) (P = 0.35) in males. IGF-1 and IGFBP-3 were positively correlated (P < 0.001). IGF-1 or IGFBP-3 Z-scores and age, hGH, estradiol, GALT activity or soy intake were not correlated. FSH was elevated in females, other axes were normal. Besides the hypergonadotropic hypogonadism in females, IGF-1 and IGFBP-3 are in the low to normal ranges in girls. Hypoglycosylation in galactosemia is diet dependent and could worsen when galactose intake increases either because of poor compliance or diet liberalization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935538     DOI: 10.1016/j.ymgme.2006.07.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  The male reproductive system in classic galactosemia: cryptorchidism and low semen volume.

Authors:  Cynthia S Gubbels; Corrine K Welt; John C M Dumoulin; Simon G F Robben; Catherine M Gordon; Gerard A J Dunselman; M Estela Rubio-Gozalbo; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

Review 2.  Galactose toxicity in animals.

Authors:  Kent Lai; Louis J Elsas; Klaas J Wierenga
Journal:  IUBMB Life       Date:  2009-11       Impact factor: 3.885

Review 3.  Ovarian function in girls and women with GALT-deficiency galactosemia.

Authors:  Judith L Fridovich-Keil; Cynthia S Gubbels; Jessica B Spencer; Rebecca D Sanders; Jolande A Land; Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

Review 4.  Endocrine manifestations related to inherited metabolic diseases in adults.

Authors:  Marie-Christine Vantyghem; Dries Dobbelaere; Karine Mention; Jean-Louis Wemeau; Jean-Marie Saudubray; Claire Douillard
Journal:  Orphanet J Rare Dis       Date:  2012-01-28       Impact factor: 4.123

Review 5.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

6.  The natural history of classic galactosemia: lessons from the GalNet registry.

Authors:  M E Rubio-Gozalbo; M Haskovic; A M Bosch; B Burnyte; A I Coelho; D Cassiman; M L Couce; C Dawson; D Demirbas; T Derks; F Eyskens; M T Forga; S Grunewald; J Häberle; M Hochuli; A Hubert; H H Huidekoper; P Janeiro; J Kotzka; I Knerr; P Labrune; Y E Landau; J G Langendonk; D Möslinger; D Müller-Wieland; E Murphy; K Õunap; D Ramadza; I A Rivera; S Scholl-Buergi; K M Stepien; A Thijs; C Tran; R Vara; G Visser; R Vos; M de Vries; S E Waisbren; M M Welsink-Karssies; S B Wortmann; M Gautschi; E P Treacy; G T Berry
Journal:  Orphanet J Rare Dis       Date:  2019-04-27       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.